Specialty Pharmacy

Tofacitinib is the first and only Janus kinase inhibitor approved by the FDA for this patient population.

In response to the increasing incidence of colorectal cancer in young and middle-aged individuals, the American Cancer Society has updated its screening recommendations.

The addition of nelarabine (Arranon) to standard chemotherapy provided further benefit for patients with moderate or high risk of disease recurrence.

The results of a recent study provide important insights into what might influence the development of multiple sclerosis.

Top news of the day from across the health care landscape.

Patients with cystic fibrosis (CF) who were treated with ivacaftor have demonstrated favorable results for clinically important outcomes, according to a new study.

New research investigates whether reducing the pill burden in HIV treatment regimens could improve patient adherence, retention in care, and virologic outcomes.

Top news of the day from across the health care landscape.

From 1990 to 2016, incident cases and deaths from multiple myeloma have grown substantially.

Transplant patients who received organs from donors who died from drug intoxication had similar survival compared with other transplant patients.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses HIV and oncology distinction programs and how these standards bring patients, physicians, and pharmacists together to align care.

A new report projects health insurance coverage losses between 2018 and 2028 for people under age 65 as a result of changes to the Affordable Care Act (ACA) by the Trump administration.

A new 5-part video series released by the FDA is part of a larger education and outreach effort about biosimilars and interchangeable products.

FDA officials have approved pegvaliase-pqpz (Palynziq, BioMarin Pharmaceutical) for adults with a rare and serious genetic disease, phenylketonuria (PKU).

Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (InO) indicated better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Researchers have identified a gene associated with the body’s circadian rhythm that may play a role in the development of breast cancer.

A look at last week's top stories in the world of pharmacy.

Two studies assessed prostate specific antigen (PSA) progression in patients treated with apalutamide (Erleada, Janssen) and the association between PSA doubling time and survival.

Researchers compared lung cancer care and outcomes, including patient characteristics, stage of cancer at diagnosis, treatment, and overall survival of patients in the United States and England.

Top news of the day from across the health care landscape.

Brain damage can begin early in infection, particularly during untreated infection, and can cause cognitive impairment.

The FDA is taking new steps to ensure products being marketed to protect consumers from the sun’s harmful effects deliver on their promises, starting with warning letters sent to companies marketing products with unproven claims.

Ixekizumab (Taltz, Eli Lilly) is the first and only treatment approved by the FDA for moderate-to-severe plaque psoriasis that includes data on psoriasis involving the genital area in its label.

Data from two phase 3 studies found that emicizumab-kxwh (Hemlibra) prophylaxis controlled bleeds in patients with hemophilia A.

Patients with severe asthma who were treated with dupilumab experienced a reduction in severe exacerbation risk, improved lung function, and reduced dependence on oral corticosteroids.

Top news of the day from across the health care landscape.

Rucaparib, an (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.

Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses the concerns regarding DIR fees and the impact it may have.